InfuSystem (INFU) Q4 2024 earnings summary

Executive summary

• Net revenues reached $134.9 million for 2024, up 7.2% year-over-year, with strong performance in oncology and pain management and Patient Services at $80.4 million (+5%) and Device Solutions at $54.5 million (+11%).

• Adjusted EBITDA rose 13% to $25.3 million, with a full-year margin of 18.8%, and operating income increased 69% to $6.9 million.

• Operating cash flow hit a record $20.5 million, up 82% year-over-year, and net income was $2.3 million ($0.11 per diluted share), up from $0.04 per share in 2023.

• Growth was broad-based, with oncology and pain management revenues up 6.1% and 14.7%, respectively; Device Solutions equipment rentals grew 13.6% and sales 20.6%, including a large one-time transaction.

• New distribution agreements with Smith+Nephew and ChemoMouthpiece expanded the product portfolio and market reach.

Financial highlights

• Q4 2024 net revenues were $33.8 million (+7% year-over-year), with Patient Services at $20.8 million (+8%) and Device Solutions at $13.1 million (+4%).

• Q4 gross profit was $18.2 million (+16%), with gross margin at 53.8% (+1.2%).

• Q4 operating income was $2.6 million (+109%), net income $0.9 million ($0.04 per diluted share), and Adjusted EBITDA $7.5 million (+22%).

• Full-year gross profit was $70.4 million (+12%), gross margin 52.2% (+2.0%), and Adjusted EBITDA margin 18.8% (+1.0%).

• Operating cash flow for 2024 was $20.5 million (+82%), with liquidity at $51.4 million as of year-end.

Outlook and guidance

• 2025 net revenue growth is projected at 8–10%, with Adjusted EBITDA margin expected to exceed 18.8%.

• Adjusted EBITDA margin could surpass 20% excluding $2.5 million in IT upgrade costs planned for 2025.

• Q1 2025 adjusted EBITDA margin expected in the mid-teens, with higher margins in the second half of the year.

• Advanced wound care, biomed, and Chemo Mouthpiece expected to drive most of the 2025 growth.

• Management notes seasonality in Q1, with lower Adjusted EBITDA and cash flow due to insurance deductible resets.